Numerous case reports and case series have documented clinically significant, and often durable, tumor responses to the combination of RT and PD-1/PD-L1 blockade in advanced or metastatic melanoma, NSCLC, Hodgkin lymphoma, RCC, and cervical cancer [103–112]. The gene discussed is CD274; the disease is neoplasm.